Patents by Inventor William Henry Miller

William Henry Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7618959
    Abstract: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: November 17, 2009
    Assignee: SmithKlineBeecham Corp
    Inventors: Jeffrey Michael Axten, Timothy Francis Gallagher, William Henry Miller, Mark Andrew Seefeld
  • Patent number: 7608621
    Abstract: The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: October 27, 2009
    Assignee: SmithKline Beecham, Corp.
    Inventors: Antony N. Shaw, Kevin J. Duffy, William Henry Miller, Andrea K. Myers, Michael N. Zimmerman
  • Patent number: 7605169
    Abstract: Napthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: October 20, 2009
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Mark Andrew Seefeld
  • Patent number: 7592334
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: September 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Publication number: 20090181955
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: March 26, 2009
    Publication date: July 16, 2009
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Patent number: 7511035
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: March 31, 2009
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Patent number: 7498326
    Abstract: Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man. The piperidine derivatives include compounds of formula (I): wherein RA, AB, n, R3, R2 and R4 are defined herein. For example, RA is an optionally substituted bicyclic carbocyclic or heterocyclic ring system, and R4 is a group U-R5 in which R5 is an optionally substituted bicyclic heterocyclic ring system as defined herein (e.g. optionally substituted pyrido [3,2, -b][1,4] thiazin-yl).
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: March 3, 2009
    Assignee: Glaxo Group Limited
    Inventors: Jeffrey Michael Axten, Robert A Daines, David Thomas Davies, Timothy Francis Gallagher, Graham Elgin Jones, William Henry Miller, Neil David Pearson, Israil Pendrak
  • Publication number: 20090054418
    Abstract: 2H-chromen-2-one derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 26, 2009
    Inventors: William Henry Miller, Alan T. Price
  • Publication number: 20080293691
    Abstract: The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Combination therapies for the treatment of ocular neovascular disorders are also encompassed.
    Type: Application
    Filed: November 29, 2006
    Publication date: November 27, 2008
    Inventors: Richard Anthony Brigandi, Mark Levick, William Henry Miller
  • Publication number: 20080214549
    Abstract: The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: January 11, 2008
    Publication date: September 4, 2008
    Inventors: Antony N. SHAW, Kevin J. Duffy, William Henry Miller, Andrea K. Myers, Michael N. Zimmerman
  • Publication number: 20080194547
    Abstract: Naphthalene, quinoline, quinoaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: July 8, 2005
    Publication date: August 14, 2008
    Applicant: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Publication number: 20080146551
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 19, 2008
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Publication number: 20080139539
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 12, 2008
    Applicant: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Publication number: 20080139540
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections, particularly humans, are disclosed herein.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 12, 2008
    Applicant: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Patent number: 7312212
    Abstract: Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: December 25, 2007
    Assignee: Glaxo Group Limited
    Inventors: Robert A Daines, William Henry Miller, Neil David Pearson, Israil Pendrak, Mark Andrew Seefeld
  • Patent number: 7232832
    Abstract: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: June 19, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Jeffrey Michael Axten, William Henry Miller, Mark Andrew Seefeld
  • Patent number: 7109213
    Abstract: Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: September 19, 2006
    Assignee: Glaxo Group Limited
    Inventors: Robert A Daines, William Henry Miller, Neil David Pearson, Israil Pendrak, Mark Andrew Seefeld
  • Patent number: 6825188
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: November 30, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Publication number: 20040082559
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 29, 2004
    Applicant: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas
  • Publication number: 20030125317
    Abstract: Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
    Type: Application
    Filed: December 16, 2002
    Publication date: July 3, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: James Francis Callahan, Russell Donovan Cousins, Richard McCulloch Keenan, Chet Kwon, William Henry Miller, Irene Nijole Uzinskas